Moreover, mGluR4 enhancer PHCCC negatively regulated the growth of three medulloblastoma cell lines (Iacovelli et al., 2006), which implicated a novel potential drug target for glioma treatment. This evidence concerns the gene GRM4 and central nervous system cancer.